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Hypocalcemia can be associated with coexisting hypomagnesemia, which induces 
hypoparathyroidism as well as resistance to parathyroid hormone (PTH). Here, we present 
two patients with severe hypomagnesemia and associated hypocalcemia, caused by proton 
pump inhibitors.
1
  
 
 
Patient A: 
Patient A was 61-year-old female, who 
was referred to our endocrinology 
department for persistent hypocalcemia.  
She reported that her calcium had been 
low for the last couple of years and it was 
as low as 1.53 mmol/l earlier this year. She 
was taking calcium and vitamin D 
supplements for some time. Her other 
medications included lansoprazole, 
alendronic acid and tramadol. She was 
admitted to a hospital once for intravenous 
calcium. She experienced tingling, 
numbness of her fingers and leg cramps. 
Her past medical history included jejunal 
bypass for obesity in 1976, chronic 
diarrhea and rheumatoid arthritis. Since the 
jejunal bypass in 1976, she had ongoing 
intermittent chronic diarrhea. She never 
had any neck irradiation, surgery or 
thyroidectomy, which could explain her 
hypoparathyroidism. Her blood test taken 
after clinic showed an inappropriately 
normal PTH of 5.1 pmol/l, in view of the 
very low adjusted calcium level at 1.53 
mmol/l,  undetectable magnesium <0.25 
mmol/l, and low 25-OH Vitamin D at 
14nmol/l. She was admitted was treated 
with intravenous magnesium, calcium and 
an intramuscular injection of ergocalciferol 
(vitamin D). After the magnesium 
replacement, PTH improved to 26.9 
pmol/l.   She was discharged, but 
unfortunately she resumed her 
lansoprazole and had to be readmitted to 
hospital for intravenous magnesium 
replacement. 
 
Patient B:              
Patient B was admitted to the hospital 
complaining of generalised malaise and 
twitching. On admission, she was found to 
be very hypomagnesemic and 
hypocalcemic. Her blood tests revealed an 
undetectable magnesium level of <0.25 
mmol/l, adjusted calcium level at 
1.67mmol/l, PTH of 5.7 pmol/l and urea of 
16.8 mmol/l. She was treated with 
intravenous magnesium and calcium, 
which corrected her magnesium and 
adjusted her calcium levels. Her repeated 
PTH came back as 23.8 pmol/l. Prior to 
this admission, her doses of furosemide 
and perindopril were also increased 
contributing to her dehydration as 
evidenced by raised urea level at 16.8 
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mmol/l. Her vitamin D was normal at 102 
nmol/l. Her past medical history included 
diastolic heart failure, hypertensive heart 
disease and dementia. She was taking 
donepezil 10mg once a day, furosemide 80 
mg once a day, perindopril 4mg once a 
day, vitamin D3 supplements and 
omeprazole 20 mg once day.  
 
DISCUSSION: 
 
Hypomagnesemia usually 
accompanied by hypocalcemia has been 
reported in patients taking PPIs, 
particularly if the duration of drug 
utilization has been more than 1 year. The 
combination of PPIs and diuretics leads to 
an increased incidence of 
hypomagnesemia.
1
  
Like calcium, magnesium plays a 
crucial role in the regulation of PTH 
secretion. These cases demonstrate the 
blunted PTH secretion in patients with 
severe hypomagnesemia.
3
 Profound 
hypomagnesemia decreases the release of 
PTH and induces skeletal resistance to 
PTH, which can result in severe 
hypocalcemia.
2
 In the first case, 
hypomagnesemia was driven by diarrhea, 
and in the second case it was caused by 
concurrent use of diuretics with a recent 
dose increase.
1
  The patients in both cases 
were taking long-term proton pump 
inhibitors, which are known to reduce 
intestinal magnesium absorption. The 
presumed mechanism is impaired 
absorption of magnesium by intestinal 
epithelial cells caused by PPI-induced 
inhibition of transient receptor potential 
melastatin-6 (TRPM6) and TRPM7 
channels.
2
  
PPI-induced hypomagnesemia 
(PPIH) leads to severe symptoms, such as 
fits, convulsions, cardiac arrhythmia and 
increased risk for concomitant secondary 
electrolyte disturbances like hypocalcemia.  
Patients have significant comorbidities and 
most of them are affected by 
polypharmacy.
3
  
Hypomagnesemia interferes with 
parathyroid hormone (PTH) release in 
response to hypocalcemia.  PTH levels in 
most hypomagnesemic - hypocalcemic 
patients have been either normal or low.
2
 
Our patients had a low initial PTH level, 
but it was back to normal after the 
correction of hypomagnesemia. The 
hypocalcemia is quite profound in these 
patients and cannot be solely explained by 
an impaired secretion of the parathyroid 
hormone. There is possible resistance of 
the parathyroid hormone that contributes 
to hypocalcemia. It is advised to check 
magnesium level in patients who are 
expected to be on PPIs for a longer 
duration and who are simultaneously 
taking other medication like dietetics and 
digoxin that impair magnesium 
absorption.
2
  
The described metabolic 
abnormalities normalized in both patients 
upon withdrawal of the proton-pump 
inhibitors, and neither patient required 
further magnesium or calcium 
supplementation. We discharged them to 
their primary care. 
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